Champions Oncology, Inc.
CSBR Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$4.86
KIRA · Stoqly’s AI analyst, in plain words
- Champions Oncology, Inc. had $59.4M of revenue in fiscal 2026, up 4.4% on the year before. Over five years, revenue changed +7.7% a year on average.
- Its operating margin was −1.9%, down 9.9 pts: of every 100 in sales, about −2 is left after running the business.
- Champions Oncology, Inc. lost $1.2M in fiscal 2026.
- Free cash flow was −$5.0M in fiscal 2026, −8.5% of revenue.
Market cap
$67.2M
P/E
—
Revenue
$59.4M
Net income
−$1.2M
Free cash flow
−$5.0M
Operating margin
−1.9%
Champions Oncology, Inc. in 30 seconds · fiscal 2026
Are sales growing?
+4.4%
Only a little. Sales grew 4.4% last year.
Does it make a profit?
−2.0%
No. It lost money last year.
Does profit turn into cash?
−8.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Champions Oncology, Inc. does
No business description yet.
- Fiscal year ends
- April 30, 2026
- Latest annual report
- 10-K · Jul 27, 2026
- Legal name
- CHAMPIONS ONCOLOGY, INC.
- CIK
- 0000771856
Champions Oncology, Inc. · CSBR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $49.1M | $53.9M | $50.2M | $56.9M | $59.4M |
| Revenue growth | 19.7% | 9.7% | −6.9% | 13.5% | 4.4% |
| Gross margin | 51.9% | 45.2% | 41.4% | 50.1% | 48.0% |
| Operating margin | 1.2% | −9.8% | −14.7% | 8.0% | −1.9% |
| Net income | $0.5M | −$5.3M | −$7.3M | $4.7M | −$1.2M |
| Net margin | 1.1% | −9.9% | −14.5% | 8.3% | −2.0% |
| Diluted EPS | $0.04 | −$0.39 | −$0.54 | $0.33 | −$0.08 |
| Cash | |||||
| Cash from operations | $6.5M | $4.0M | −$6.1M | $7.4M | −$4.5M |
| Capital expenditure | $2.4M | $2.9M | $0.8M | $0.4M | $0.6M |
| Free cash flow | $4.1M | $1.1M | −$7.0M | $7.0M | −$5.0M |
| FCF margin | 8.4% | 2.0% | −13.9% | 12.3% | −8.5% |
| Share buybacks | $0.0M | $0.1M | $0.6M | $0.0M | — |
| Share count change | −2.8% | −4.4% | 0.0% | 5.3% | −3.0% |
| Debt and strength | |||||
| Cash and short-term investments | $9.0M | $10.1M | $2.6M | $9.8M | $4.9M |
| Shareholders' equity | $9.1M | $4.6M | −$1.9M | $3.8M | $3.9M |
| Current ratio | 1.1x | 0.9x | 0.6x | 0.9x | 1.0x |
| Returns and quality | |||||
| Return on equity | 6.6% | −77.7% | −532.5% | 503.0% | −30.5% |
| Return on tangible equity | 6.3% | −124.0% | — | 136.8% | −32.6% |
| Piotroski F-score | 6 | 4 | 2 | 6 | 3 |
| Altman Z'' | −5.7 | −8.6 | −14.5 | −7.3 | −10.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Champions Oncology, Inc. · CSBR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.86 a share, the company is worth $67.2M.
Source: SEC EDGAR XBRL filings (CIK 0000771856). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.